Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ClpC2 is a regulatory protein and partial homologue of the essential AAA+ ATPase ClpC1 found in Mycobacterium tuberculosis and other actinobacteria. Unlike ClpC1, which is a core component of the ClpCP protease complex required for protein degradation, ClpC2 lacks the full ATPase motor domains and primarily functions as a transcriptional repressor and a 'molecular sponge.' Under standard growth conditions, ClpC2 represses its own transcription; however, upon exposure to certain natural antibiotics like Cyclomarin A or Rufomycin, the drug binds to ClpC2 and relieves this repression. This leads to a massive upregulation of ClpC2, which then sequesters the antibiotic molecules to prevent them from inhibiting the essential ClpC1 target, thereby protecting the bacterial proteostasis system. This sequestration mechanism represents a significant therapeutic challenge, as it reduces the effective concentration of Clp-targeting drugs. Recent drug development efforts have focused on using BacPROTACs (Bacterial Proteolysis Targeting Chimeras) to induce the simultaneous degradation of both ClpC1 and its ClpC2 caretaker, effectively bypassing this intrinsic resistance mechanism to kill the pathogen.
ClpC2 acts as a molecular sponge by sequestering antibiotics away from the essential ClpC1 target; it also functions as a transcriptional repressor that upregulates itself upon drug binding; BacPROTACs target ClpC2 for degradation to overcome this resistance mechanism.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ATP-dependent protease ATP-binding subunit ClpC2 (ClpC2).